HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.0%

Neg 0% Neu 91% Pos 0%

HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Buy and maintains $38 price target.